^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MYC negative

    i
    Other names: MYC, bHLHe39, c-Myc, MYCC, V-myc avian myelocytomatosis viral oncogene homolog
    Entrez ID:
    4609
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    1d
    Immunodeficiency-related high-grade B-cell lymphoma with 11q aberration: Further evidence for a lymphoma entity from a patient with simultaneous papillary renal cell carcinoma following pediatric kidney transplant. (PubMed, Pathol Res Pract)
    While we can show that the imbalances in 8q and 11q arise from different mechanisms in both tumors, trisomy 12 involved gain of the same parental chromosome. Our findings corroborate the existence of a subtype of immunodeficiency-related high-grade B-cell lymphomas with 11q aberrations, provide further insights into its molecular pathogenesis, and reveal potential pitfalls in the molecular diagnosis of simultaneous tumors based on the technology applied.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog)
    |
    MYC negative • TS 12
    2ms
    HPV16 integration regulates ferroptosis resistance via the c-Myc/miR-142-5p/HOXA5/SLC7A11 axis during cervical carcinogenesis. (PubMed, Cell Biosci)
    Collectively, these data indicate that HPV16 integration hot spot c-Myc plays a novel and indispensable role in ferroptosis resistance by regulating the miR-142-5p/HOXA5/SLC7A11 signalling axis and suggest a potential therapeutic approach for HPV16 integration-related CSCC.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MIR142 (MicroRNA 142) • SLC7A11 (Solute Carrier Family 7 Member 11)
    |
    MYC expression • miR-142 overexpression • MYC negative
    |
    erastin
    3ms
    Phospholipase Cδ-4 (PLCδ4) Acts as a Nuclear Player to Influence Cyclin B Expression in the Embryonal Rhabdomyosarcoma Cell Lines RD and A204. (PubMed, Biomolecules)
    Our study identifies a novel role for nuclear PLCδ4 as a regulator of cyclin B1 via Akt-dependent phosphorylation. The modulation of PLCδ4 expression and its downstream targets could represent a crucial signaling pathway to block embryonal RMS cell proliferation.
    Preclinical • Journal
    |
    TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • CHEK2 (Checkpoint kinase 2) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • WNK1 (WNK Lysine Deficient Protein Kinase 1) • AKT1S1 (AKT1 Substrate 1) • CCNB1 (Cyclin B1)
    |
    TP53 mutation • MYC amplification • MYC expression • TP53 expression • MYC negative
    4ms
    MYC is sufficient to generate mid-life high-grade serous ovarian and uterine serous carcinomas in a p53-R270H mouse model. (PubMed, Cancer Res Commun)
    This new mouse model enables further exploration of ovarian cancer pathogenesis, particularly in the 50% of HGSOC which lack homology directed repair mutations. Histological and transcriptomic findings are consistent with the hypothesis that uterine serous cancer may originate from the fallopian tube epithelium.
    Preclinical • Journal
    |
    TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog)
    |
    TP53 mutation • MYC expression • MYC negative
    8ms
    Testing for t(3;8) in MYC/BCL6 re-arranged large B cell lymphoma identifies a high risk subgroup with inferior survival. (PubMed, Blood)
    A reciprocal t(3;8) BCL6::MYC fusion is common in large B cell lymphoma (LBCL) with MYC and BCL6 disruption. These pseudo-double hit cases are not adverse, whereas t(3;8) negative MYC/BCL6 lymphoma has an inferior prognosis relative to other MYC-rearranged LBCL.
    Journal
    |
    BCL6 (B-cell CLL/lymphoma 6)
    |
    MYC negative
    8ms
    Latent Epstein-Barr virus infection collaborates with Myc over-expression in normal human B cells to induce Burkitt-like Lymphomas in mice. (PubMed, PLoS Pathog)
    These results show that latent EBV infection collaborates with Myc over-expression to induce BL-like human B-cell lymphomas in mice. As NF-κB signaling retards the growth of EBV-negative BLs, Myc-mediated repression of LMP1 may be essential for latent EBV infection and Myc translocation to collaboratively induce human BLs.
    Preclinical • Journal
    |
    TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL6 (B-cell CLL/lymphoma 6) • STAT3 (Signal Transducer And Activator Of Transcription 3) • BCL2L11 (BCL2 Like 11) • TCF3 (Transcription Factor 3) • MME (Membrane Metalloendopeptidase) • DNMT3B (DNA Methyltransferase 3 Beta) • BACH2 (BTB Domain And CNC Homolog 2) • CD40LG (CD40 ligand) • IL21 (Interleukin 21) • UHRF1 (Ubiquitin Like With PHD And Ring Finger Domains 1)
    |
    TP53 mutation • TP53 wild-type • MYC expression • MYC translocation • MYC negative
    10ms
    Comparison of genomic alterations in Epstein-Barr virus-positive and Epstein-Barr virus-negative diffuse large B-cell lymphoma. (PubMed, Cancer Med)
    Our results confirm that genomic alteration differs significantly between EBV-posDLBCL and EBV-negDLBCL, and reveal new genetic alterations in EBV-posDLBCL. The positive correlation of c-MET and PD-L1/c-Myc expression may be involved in the pathogenesis of EBV-posDLBCL, which is should be explored prospectively in trials involving MET-directed therapies.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • MET (MET proto-oncogene, receptor tyrosine kinase) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • JAK2 (Janus kinase 2) • PIM1 (Pim-1 Proto-Oncogene) • DCAF8L1 (DDB1 And CUL4 Associated Factor 8 Like 1)
    |
    PD-L1 expression • MET expression • MYC expression • MYC positive • MYC negative
    10ms
    Mutational, immune microenvironment, and clinicopathological profiles of diffuse large B-cell lymphoma and follicular lymphoma with BCL6 rearrangement. (PubMed, Virchows Arch)
    In conclusion, both BCL6-R-positive FL and BCL6-R-positive DLBCL had a common mutational profile; but also, differences. DLBCL cases had a higher density of microenvironment markers.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • BCL2 (B-cell CLL/lymphoma 2) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • NOTCH1 (Notch 1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • BCL6 (B-cell CLL/lymphoma 6) • KMT2D (Lysine Methyltransferase 2D) • NOTCH2 (Notch 2) • CREBBP (CREB binding protein) • CD163 (CD163 Molecule) • ARID1B (AT-Rich Interaction Domain 1B) • CD36 (thrombospondin receptor) • IL10 (Interleukin 10) • RHOA (Ras homolog family member A) • PIM1 (Pim-1 Proto-Oncogene) • CSF1R (Colony stimulating factor 1 receptor) • HLA-B (Major Histocompatibility Complex, Class I, B) • H1-4 (H1.4 Linker Histone, Cluster Member) • PLOD2 (procollagen-lysine,2-oxoglutarate 5-dioxygenase 2) • BTG2 (BTG Anti-Proliferation Factor 2) • LAIR1 (Leukocyte Associated Immunoglobulin Like Receptor 1)
    |
    ATM mutation • MYD88 L265P • BCL6 rearrangement • ARID1B mutation • IL10-L • PIM1 mutation • MYC negative
    10ms
    C-Myc protein expression indicates unfavorable clinical outcome in surgically resected small cell lung cancer. (PubMed, World J Surg Oncol)
    Our study provides insights into the clinical aspects of Myc family members in surgically resected SCLC tumors. Notably, besides showing that positivity of Myc family members varies across the patients, we also reveal that C-Myc protein expression independently correlates with worse survival outcomes. Further studies are warranted to investigate the role of Myc family members as potential prognostic and predictive markers in this hard-to-treat disease.
    Clinical data • Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • YAP1 (Yes associated protein 1) • MYCL (MYCL Proto-Oncogene BHLH Transcription Factor) • POU2F3 (POU Class 2 Homeobox 3) • ASCL1 (Achaete-Scute Family BHLH Transcription Factor 1) • NEUROD1 (Neuronal Differentiation 1)
    |
    MYC expression • MYC positive • MYC negative
    11ms
    Yin Yang 1 expression predicts a favourable survival in diffuse large B-cell lymphoma. (PubMed, Heliyon)
    As an independent prognostic factor, YY1 expression could predict a favourable outcome in DLBCL. In addition, a complex regulatory mechanism might be involved in the interactions between YY1 and MYC, pAKT as well as CXCR4 in DLBCL, which warrants further investigation.
    Journal • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • CXCR4 (Chemokine (C-X-C motif) receptor 4) • IRF4 (Interferon regulatory factor 4) • YY1 (YY1 Transcription Factor)
    |
    BCL2 expression • MYC expression • CXCR4 expression • MYC negative
    12ms
    Clinical study of mature B-cell lymphoma in 11 children with chromosome 11 long-arm abnormalities (PubMed, Zhonghua Xue Ye Xue Za Zhi)
    The incidence of MBCL with 11q abnormalities in children is low, clinical symptoms are mild, and progression is slow. The absence of MYC, BCL2, BCL6 rearrangements, C-MYC negative and 11q abnormalities on FISH is an important diagnostic indicator, and reducing the intensity of chemotherapy can improve prognosis.
    Journal • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    MYC expression • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement • MYC positive • MYC negative
    12ms
    A MYC-rearrangement is a negative prognostic factor in stage II, but not in stage I diffuse large B-cell lymphoma. (PubMed, Blood Cancer J)
    We identified 1,434 LS DLBCL patients with known MYC-R status diagnosed between 2014 and 2020, who received R-CHOP(-like) regimens using the Netherlands Cancer Registry, with survival follow-up until February 2022...In stage I DLBCL, however, survival outcomes are excellent irrespective of MYC-R status. This challenges the diagnostic assessment of MYC-R in stage I DLBCL patients.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement • MYC negative
    |
    Rituxan (rituximab)
    12ms
    A rare case of fluid overload-associated large B-cell lymphoma and antigen loss at relapse. (PubMed, J Hematop)
    FO-LBCL patients generally have a more favorable prognosis compared to PEL. In this case, the patient exhibited a favorable prognosis for over 22 months without additional treatment apart from pleural drainage.
    Journal • IO biomarker
    |
    ALK (Anaplastic lymphoma kinase) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • TNFRSF8 (TNF Receptor Superfamily Member 8) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • IGH (Immunoglobulin Heavy Locus) • CD38 (CD38 Molecule) • CD79B (CD79b Molecule) • PAX5 (Paired Box 5) • CD5 (CD5 Molecule) • SDC1 (Syndecan 1) • CCND3 (Cyclin D3) • CD79A (CD79a Molecule) • IRF4 (Interferon regulatory factor 4) • MME (Membrane Metalloendopeptidase)
    |
    CD20 positive • BCL6 rearrangement • CD79B mutation • MYC negative
    12ms
    Monomorphic epitheliotropic intestinal T-cell lymphoma involving the central nervous system: a rare case report with comprehensive autopsy neuropathological examinations. (PubMed, J Hematop)
    The histology and immunophenotype confirmed the MEITL brain involvement. Neurologic decline and cognitive changes in patients with known MEITL can be the first clue of brain involvement upon which prompt evaluation is warranted.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CD20 (Membrane Spanning 4-Domains A1) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • NCAM1 (Neural cell adhesion molecule 1) • CD5 (CD5 Molecule) • CD7 (CD7 Molecule)
    |
    MYC negative
    1year
    A051701: Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas (clinicaltrials.gov)
    P2/3, N=363, Active, not recruiting, National Cancer Institute (NCI) | Suspended --> Active, not recruiting
    Enrollment closed
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    BCL2 expression • MYC expression • MYC translocation • MYC negative • BCL2 translocation
    |
    Venclexta (venetoclax) • Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • Mabtas (rituximab biosimilar)
    1year
    Analysis of 9 cases of pediatric-type follicular lymphoma (PubMed, Zhonghua Er Ke Za Zhi)
    PTFL is mainly characterized by adolescent male onset, with early clinical manifestations and pathological manifestations of high-level histological status, high proliferation index, and lack of t (14; 18)/Bcl-2 translocation and Bcl-2 expression. It is mainly treated by localized surgical excision and has a good prognosis.
    Journal • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • BCL6 (B-cell CLL/lymphoma 6) • MME (Membrane Metalloendopeptidase)
    |
    CD20 positive • BCL2 expression • BCL2 positive • MYC translocation • MYC negative • BCL2 translocation
    1year
    Molecular and clinicopathological features of granzyme B-negative extranodal NK/T-cell lymphoma. (PubMed, Hum Pathol)
    In conclusion, GZMB expression is highly heterogeneous in ENKTLs and is associated with the activation of the JAK-STAT3 pathway and higher MYC expression. GZMB-negative ENKTLs correlate with an advanced clinical stage, suggesting the potential utility of GZMB immunohistochemistry as a biomarker of ENKTL.
    Journal • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • IL6 (Interleukin 6) • GZMB (Granzyme B) • PRF1 (Perforin 1) • TRG (T Cell Receptor Gamma Locus)
    |
    MYC expression • MYC positive • MYC negative • GZMB negative
    1year
    Genetic analysis of two cases with MYC "negative" Burkitt lymphoma (PubMed, Zhonghua Yi Xue Yi Chuan Xue Za Zhi)
    The separate probe for the MYC gene has some shortcomings and should be used together with dual fusion probe to improve the accuracy of diagnosis.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog)
    |
    MYC translocation • MYC negative
    1year
    Comparing Clinical Characteristics and Outcomes of MYC and BCL6 Double Hit Lymphoma (DHL-BCL6) with Other Aggressive B-Cell Lymphomas: Understanding the Impact of New Who and International Consensus Classifications (ASH 2023)
    Patients with DHL-BCL6 were younger at diagnosis (median 60 years), had more extranodal site involvement (40%), more often stage III/IV disease (70%), and more often treated with a higher intensity regimen than R-CHOP (69%) compared to DLBCL,NOS and MYC-R DLBCL... Our data support separating DHL-BCL6 from DHL-BCL2 as these patients form a unique subgroup with some clinical characteristics comparable to both DLBCL, NOS as well as HGBL, NOS and DHL-BCL2 subtypes. In this cohort, clinical outcomes are more comparable to DLBCL, NOS than DHL-BCL2 or HGBCL, NOS. More frequent use of intensive chemotherapy in DHL-BCL6 compared with DLBCL may account for this finding, although larger multicenter studies are needed.
    Clinical
    |
    BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    LDH elevation • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement • MYC negative
    |
    Rituxan (rituximab)
    1year
    Ulcerated groin plaque as the presenting symptom for stage IV diffuse large B-cell lymphoma (DLBCL) (ASDP 2023)
    With a preliminary diagnosis of primary cutaneous DLBCL, positron emission tomography (PET) scan was conducted that showed intense uptake in the groin lymph nodes and multifocal femur uptake concerning for osseous marrow involvement.  Accordingly, a diagnosis of systemic DLBCL was made.  The findings of CD5 positivity, dual expression of BCL-2 and C-Myc, and markedly elevated Ki-67 proliferative index are associated with a worse clinical outcome.  The cutaneous presentation and requirement of interdisciplinary collaboration highlight the importance of clinicopathologic correlation for accurate diagnosis. Poster type: Poster Defense
    IO biomarker • Metastases
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • TNFRSF8 (TNF Receptor Superfamily Member 8) • CCND1 (Cyclin D1) • BCL6 (B-cell CLL/lymphoma 6) • CD5 (CD5 Molecule) • IRF4 (Interferon regulatory factor 4) • MME (Membrane Metalloendopeptidase) • SOX11 (SRY-Box Transcription Factor 11)
    |
    MYD88 mutation • BCL2 expression • MYC expression • CD5 positive • MYC negative
    over1year
    Androgen receptor and MYC transcriptomes are equilibrated in multilayer regulatory circuitries in prostate cancer. (PubMed, Prostate)
    Together, our findings stratified AR-MYC interactions that are extensively wired and intricately organized to compensate for essential PCa transcriptional programs and neutralize excessive signaling.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • AR (Androgen receptor)
    |
    MYC negative
    over1year
    Inhibition of cMYC-MAX transcription factors hetero-dimerization with structurally engineered omoMYC to downregulate oncogenic pathways in renal carcinoma. (PubMed, Comput Biol Med)
    Additionally, the internal motion and energy landscape were altered. These findings provide important insights into the potential of the mutants of OmoMyc as a therapeutic candidate for cancer treatment, particularly renal carcinoma, and could pave the way for the development of more effective clinical versions of OmoMyc.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog)
    |
    MYC negative
    over1year
    Comprehensive genomic analysis of primary bone sarcomas reveals different genetic patterns compared with soft tissue sarcomas. (PubMed, Front Oncol)
    Additionally, comprehensive genetic landscape can provide novel treatment perspectives for primary bone sarcoma and STS. Taking TMB, MSI, PD-L1 expression, and OncoKB definition together into consideration, there are still many patients who have the potential to respond to targeted therapy or immunotherapy.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • MET (MET proto-oncogene, receptor tyrosine kinase) • MSI (Microsatellite instability) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • PTEN (Phosphatase and tensin homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • LRP1B (LDL Receptor Related Protein 1B) • CDK4 (Cyclin-dependent kinase 4) • CDKN2B (Cyclin Dependent Kinase Inhibitor 2B) • EWSR1 (EWS RNA Binding Protein 1) • MAP3K1 (Mitogen-Activated Protein Kinase Kinase Kinase 1)
    |
    PD-L1 expression • TMB-H • MET amplification • MYC negative
    over1year
    NIPSNAP1 directs dual mechanisms to restrain senescence in cancer cells. (PubMed, J Transl Med)
    Together, these findings reveal NIPSNAP1 as an important mediator of c-Myc function and a negative regulator of cellular senescence. These findings also provide a theoretical basis for cancer therapy where targeting NIPSNAP1 invokes cellular senescence.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • SIRT3 (Sirtuin 3) • SOD2 (Superoxide Dismutase 2)
    |
    MYC negative
    over1year
    Omomyc downregulates MYC transcriptional signature in preclinical models of solid tumours and shows long half-life in patient-derived tumour tissues (EACR 2023)
    In line with the preclinical observations, we also confirmed the presence of Omomyc in patients' biopsies.ConclusionOur results show evidence of the long-lasting half-life of functional Omomyc in patient-derived tumour tissues, suggestive of a different PK profile between serum and tissue. We also demonstrate in vivo target engagement and the therapeutic utility of this pan-MYC inhibitor in lung, colon and breast cancer models.
    Preclinical
    |
    MYC negative
    over1year
    Primary Angiosarcoma of the Breast Diagnosed on Core Needle Biopsy: A Diagnostic Challenge. (PubMed, Int J Surg Pathol)
    Among them, anastomosing vascular spaces with infiltrated growth pattern especially invasion into the breast intralobular stroma and adipose tissue was the most common character of angiosarcomas which alert the possibility of malignancy in core needle biopsy. However, an accurate diagnosis demands integration of various histological clues and multidisciplinary discussion.
    Journal • Biopsy
    |
    CD34 (CD34 molecule) • CD31 (Platelet and endothelial cell adhesion molecule 1) • PECAM1 (Platelet And Endothelial Cell Adhesion Molecule 1)
    |
    MYC negative
    over1year
    Association between Sanjad Sakati syndrome and congenital neuroblastoma in children (ASPHO 2023)
    HRD is a very rare condition that is caused by a mutation in the TBCE gene. This is the second case reporting the association between HRD and neuroblastoma and the first case discussing the management of neuroblastoma in patients with HRD. The presence of neuroblastoma with HRD makes treatment difficult and reduces the patient's ability to tolerate treatment.
    Clinical
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MYCN (MYCN Proto-Oncogene BHLH Transcription Factor) • IGF1 (Insulin-like growth factor 1)
    |
    MYC expression • MYC negative
    over1year
    CCAT 1- A Pivotal Oncogenic Long Non-Coding RNA in Colorectal Cancer. (PubMed, Br J Biomed Sci)
    Furthermore, dysregulated CCAT 1 also enhances the chemoresistance in CRC cells while downregulation of them reverses the malignant phenotypes of cancer cells. In brief, CCAT 1 serves as a potential screening, diagnostic and prognostic biomarker in CRC, it also serves as a potential therapeutic marker to treat CRC patients.
    Review • Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CCAT1 (Colon Cancer Associated Transcript 1)
    |
    MYC negative
    almost2years
    Nanocage delivered engineered destabilized 3UTR ARE of cMYC inhibits triple negative breast cancer growth and metastasis in vivo by targeting cMYC and downregulating STAT5A5B (AACR 2023)
    Mechanistically, the destabilization of c-MYC degraded c-MYC and its super enhancer interacting partner, STAT5A/B, in primary tumors and metastatic tumors. Taken together, we have developed a novel therapy for TNBC and uncovered c-MYC super enhancer STAT5A/B interaction as the target
    Preclinical
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CASP3 (Caspase 3) • CASP7 (Caspase 7) • STAT5A (Signal Transducer And Activator Of Transcription 5A)
    |
    MYC overexpression • MYC negative
    almost2years
    Development of a Prognostic Scoring System using MYC Expression and Soluble Interleukin Receptor -2 level for Diffuse Large B-cell Lymphoma. (PubMed, Yonago Acta Med)
    A total of 110 patients diagnosed with DLBCL-NOS from 2012 to 2020 at Tottori University Hospital and treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) chemotherapy were included. The 2-year survival rates were 100%, 83.0%, and 47.1% for the groups 1, 2, and 3, respectively (P < 0.0001). We suggest that a prognostic scoring system using MYC expression and soluble interleukin receptor -2 level is useful for the prediction of prognosis, contributing to further stratification in DLBCL-NOS.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • IL2 (Interleukin 2)
    |
    MYC expression • MYC positive • MYC negative
    |
    Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • vincristine
    almost2years
    Genomic screening reveals ubiquitin-like modifier activating enzyme 1 as a potent and druggable target in c-MYC-high triple negative breast cancer models. (PubMed, PNAS Nexus)
    In five patient derived xenograft models (PDXs) of TNBC, TAK-243 therapy led to tumor inhibition or frank tumor regression. Moreover, in an intracardiac metastatic model of TNBC, TAK-243 markedly reduced metastatic burden, indicating UBA1 is a potential new target in TNBC expressing high levels of c-MYC.
    Preclinical • Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • ATF4 (Activating Transcription Factor 4)
    |
    MYC expression • MYC negative
    |
    TAK-243
    almost2years
    MYC Causes Multiple Myeloma Progression via Attenuating TP53-Induced MicroRNA-34 Expression. (PubMed, Genes (Basel))
    Using the nutlin-3 or Tet-on systems, we caused wild-type (WT) p53 protein accumulation in human MM cell lines (HMCLs) and observed upregulated miR-34 expression...Our results suggest that MYC participates in the suppression of p53-dependent miRNA expressions. Because miRNA expression suppresses tumors, its inhibition leads to MM development and malignant transformation.
    Journal
    |
    TP53 (Tumor protein P53) • MIR34A (MicroRNA 34a-5p)
    |
    TP53 wild-type • MYC expression • TP53 expression • MYC negative • miR-34a expression
    |
    Nutlin-3
    almost2years
    A new thinking: deciphering the aberrance and clinical implication of copper-death signatures in clear cell renal cell carcinoma. (PubMed, Cell Biosci)
    The activation of cuprotosis might function as a promising approach among multiple cancers. The cuprotosis related signatures could reshape tumor immunity in the ccRCC microenvironment via cGAS-STING signal, thus activating tumor antigen-presenting process. Upregulation of DLAT expression in ccRCC cell lines could reactivate the copper death pattern and be treated as a suitable target for ccRCC.
    Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • DLAT (Dihydrolipoamide S-Acetyltransferase)
    |
    MYC negative
    almost2years
    Transcriptional and Clinicopathological Implications of Granzyme B (GZMB)-negativity in Extranodal NK/T-cell lymphoma (USCAP 2023)
    GEP and IHC showed that GZMB expression is highly heterogeneous in ENKTLs and associated with activation of JAK-STAT3 signaling and higher MYC expression. GZMB-negative ENKTL has distinct GEP and advanced clinical stage, although not prognostically significant in our dataset. These findings imply that GZMB is a potential biomarker mirroring a certain molecular subtype of ENKTL.
    Clinical • IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • IL6 (Interleukin 6) • GZMB (Granzyme B) • PRF1 (Perforin 1)
    |
    MYC expression • MYC negative • GZMB negative
    |
    nCounter® PanCancer Pathways Panel
    2years
    Expression of p-STAT3 and c-Myc correlates with P2-HNF4α expression in nonalcoholic fatty liver disease (NAFLD). (PubMed, Oncotarget)
    Based on these results, we hypothesize with the following sequence of events with progression of NAFLD: P2-HNF4α expression is followed by expression of p-STAT3 which in turn is followed by the expression of c-Myc. Additional larger studies are needed to confirm these findings.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • STAT3 (Signal Transducer And Activator Of Transcription 3)
    |
    MYC expression • MYC positive • MYC negative
    2years
    Two cases of primary diffuse large B-cell lymphoma of the CNS associated with t(8;14)(q24;q32) or t(3;14)(q27;q32) identified by G-banding and fluorescence in situ hybridization applied to metaphase spreads. (PubMed, J Clin Exp Hematop)
    Case 1 carried the MYD88 mutation. This case report provides clear evidence for the occurrence of t(8;14)(q24;q32) and t(3;14)(q27;q32) in PCNS-DLBCL using metaphase-based cytogenetic analysis.
    Journal • IO biomarker
    |
    BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • BCL6 (B-cell CLL/lymphoma 6) • CD5 (CD5 Molecule) • CD79A (CD79a Molecule) • IRF4 (Interferon regulatory factor 4) • MME (Membrane Metalloendopeptidase)
    |
    CD20 positive • MYD88 mutation • MYC negative
    2years
    Do Unbalanced MYC Break-Apart FISH Patterns Indicate the Presence of a MYC Rearrangement? (ASH 2022)
    While detection of a translocation in sequencing data can be limited by factors such as poor biopsy quality, a translocation partner was identified for the majority of tumors with LR and LG patterns, with all but 1 translocation preserving the MYC gene. These results support that LR and LG patterns should be interpreted as a positive MYC FISH result.
    IO biomarker
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
    |
    MYC rearrangement + BCL2 rearrangement • BCL2 expression • MYC expression • MYC rearrangement + BCL6 rearrangement • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement • MYC positive • MYC negative
    2years
    c-Myc plays a critical role in the antileukemic activity of the Mcl-1-selective inhibitor AZD5991 in acute myeloid leukemia. (PubMed, Apoptosis)
    The combination also showed promising and synergistic antileukemic activity in vitro against AML cell lines with acquired resistance to the main chemotherapeutic drug AraC and primary AML cells derived from a patient at relapse post chemotherapy. The oncoprotein c-Myc represents a potential biomarker of AZD5991 sensitivity and inhibition of c-Myc synergistically enhances the antileukemic activity of AZD5991 against AML.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog) • MCL1 (Myeloid cell leukemia 1)
    |
    MYC overexpression • MCL1 overexpression • MYC expression • MYC negative
    |
    AZD5991
    2years
    The miR-3648/FRAT1-FRAT2/c-Myc negative feedback loop modulates the metastasis and invasion of gastric cancer cells. (PubMed, Oncogene)
    In addition, miR-3648 expression levels were negatively correlated with c-Myc, FRAT1, and FRAT2 expression in fresh gastric samples. Our studies suggest that miR-3648 acts as a tumour-suppressive miRNA and that the miR-3648/FRAT1-FRAT2/c-Myc negative feedback loop could be a critical regulator of GC progression.
    Journal
    |
    MYC (V-myc avian myelocytomatosis viral oncogene homolog)
    |
    MYC overexpression • MYC expression • MYC negative